Brought to you by 
Protagonist partners IBD compound PTG200 with Janssen Biotech; deal expanded
02 Dec 2021
Executive Summary
In a potential $990mm deal, Protagonist Therapeutics Inc. is licensing Janssen Biotech Inc. exclusive global rights to develop, manufacture, and commercialize its PTG200 and related interleukin-23 receptor antagonists for all indications including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Marketing
- Includes Royalty or Profit Split Information
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Protagonist partners IBD compound PTG200 with Janssen Biotech; deal expanded
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice